These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 30031992)
21. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Ou SI; Lee TK; Young L; Fernandez-Rocha MY; Pavlick D; Schrock AB; Zhu VW; Milliken J; Ali SM; Gitlitz BJ Lung Cancer; 2017 Apr; 106():110-114. PubMed ID: 28285684 [TBL] [Abstract][Full Text] [Related]
22. Benign form of myasthenia gravis after nivolumab treatment. Sciacca G; Nicoletti A; Rampello L; Noto L; Parra HJ; Zappia M Muscle Nerve; 2016 Sep; 54(3):507-9. PubMed ID: 27287688 [No Abstract] [Full Text] [Related]
23. Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. Shaw AT; Friboulet L; Leshchiner I; Gainor JF; Bergqvist S; Brooun A; Burke BJ; Deng YL; Liu W; Dardaei L; Frias RL; Schultz KR; Logan J; James LP; Smeal T; Timofeevski S; Katayama R; Iafrate AJ; Le L; McTigue M; Getz G; Johnson TW; Engelman JA N Engl J Med; 2016 Jan; 374(1):54-61. PubMed ID: 26698910 [TBL] [Abstract][Full Text] [Related]
24. The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Mok TSK; Crino L; Felip E; Salgia R; De Pas T; Tan DSW; Chow LQM Cancer Treat Rev; 2017 Apr; 55():181-189. PubMed ID: 28427013 [TBL] [Abstract][Full Text] [Related]
25. Lorlatinib: a new treatment option for ROS1-positive lung cancer. Duruisseaux M Lancet Oncol; 2019 Dec; 20(12):1622-1623. PubMed ID: 31669156 [No Abstract] [Full Text] [Related]
26. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Lau KH; Kumar A; Yang IH; Nowak RJ Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302 [TBL] [Abstract][Full Text] [Related]
27. ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers. Roskoski R Pharmacol Res; 2017 Jul; 121():202-212. PubMed ID: 28465216 [TBL] [Abstract][Full Text] [Related]
28. How might treatment of ALK-positive non-small cell lung cancer change in the near future? Metro G; Bellezza G; Puma F; Chiari R Expert Rev Anticancer Ther; 2016 Oct; 16(10):997-9. PubMed ID: 27534579 [No Abstract] [Full Text] [Related]
29. [Lorlatinib: a promising drug in the future treatment of advanced ALK-positive non-small-cell lung cancer]. Richter J; Dunst J Strahlenther Onkol; 2021 Jul; 197(7):657-660. PubMed ID: 34110434 [No Abstract] [Full Text] [Related]
30. Lorlatinib: a new-generation drug for ALK-positive NSCLC. Waqar SN; Morgensztern D Lancet Oncol; 2018 Dec; 19(12):1555-1557. PubMed ID: 30413381 [No Abstract] [Full Text] [Related]
31. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. Cooper DS; Meriggioli MN; Bonomi PD; Malik R J Neuromuscul Dis; 2017; 4(2):169-173. PubMed ID: 28505981 [TBL] [Abstract][Full Text] [Related]
40. A possible mechanism of hyperlipidemia in a patient with metastatic non-small cell lung cancer on lorlatinib therapy. McGee K; Stone NJ; Wadhwani S; Kanwar YS; Villaflor V; Akhter N J Oncol Pharm Pract; 2021 Dec; 27(8):2010-2013. PubMed ID: 33789526 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]